OKT3 is a very effective drug when used for reversal of acute allograft rejection. The excellent long-term graft survival of the patients in this study indicates that it is also an effective adjunctive therapy for promoting long-term graft survival. The problems encountered with early rerejection in high responder patients will promote an alteration of currently used protocols to accommodate these patients.
|Original language||English (US)|
|Number of pages||3|
|Issue number||1 I|
|State||Published - Jan 1 1985|
ASJC Scopus subject areas